89 related articles for article (PubMed ID: 7553680)
1. T/Tn antigen vaccine is effective and safe in preventing recurrence of advanced breast carcinoma.
Springer GF; Desai PR; Spencer BD; Tegtmeyer H; Carlstedt SC; Scanlon EF
Cancer Detect Prev; 1995; 19(4):374-80. PubMed ID: 7553680
[TBL] [Abstract][Full Text] [Related]
2. T/Tn antigen vaccine is effective and safe in preventing recurrence of advanced human breast carcinoma.
Springer GF; Desai PR; Tegtmeyer H; Carlstedt SC; Scanlon EF
Cancer Biother; 1994; 9(1):7-15. PubMed ID: 7812359
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine.
Holmberg LA; Oparin DV; Gooley T; Lilleby K; Bensinger W; Reddish MA; MacLean GD; Longenecker BM; Sandmaier BM
Bone Marrow Transplant; 2000 Jun; 25(12):1233-41. PubMed ID: 10871727
[TBL] [Abstract][Full Text] [Related]
4. Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy.
Chan AK; Wong A; Jenken D; Heine J; Buie D; Johnson D
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):665-77. PubMed ID: 15708244
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical expression of T, Tn and sialyl-Tn antigens and clinical outcome in human breast carcinoma.
Imai J; Ghazizadeh M; Naito Z; Asano G
Anticancer Res; 2001; 21(2B):1327-34. PubMed ID: 11396208
[TBL] [Abstract][Full Text] [Related]
6. Treatment of maxillary sinus carcinoma: a comparison of the 1997 and 1977 American Joint Committee on cancer staging systems.
Le QT; Fu KK; Kaplan M; Terris DJ; Fee WE; Goffinet DR
Cancer; 1999 Nov; 86(9):1700-11. PubMed ID: 10547542
[TBL] [Abstract][Full Text] [Related]
7. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.
López MN; Pereda C; Segal G; Muñoz L; Aguilera R; González FE; Escobar A; Ginesta A; Reyes D; González R; Mendoza-Naranjo A; Larrondo M; Compán A; Ferrada C; Salazar-Onfray F
J Clin Oncol; 2009 Feb; 27(6):945-52. PubMed ID: 19139436
[TBL] [Abstract][Full Text] [Related]
8. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features.
Middleton LP; Amin M; Gwyn K; Theriault R; Sahin A
Cancer; 2003 Sep; 98(5):1055-60. PubMed ID: 12942575
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival.
Cance WG; Carey LA; Calvo BF; Sartor C; Sawyer L; Moore DT; Rosenman J; Ollila DW; Graham M
Ann Surg; 2002 Sep; 236(3):295-302; discussion 302-3. PubMed ID: 12192316
[TBL] [Abstract][Full Text] [Related]
10. Further studies on the detection of early lung and breast carcinoma by T antigen.
Springer GF; Fry WA; Desai PR; Semerdjian RA; Tegtmeyer H; Neybert CG; Scanlon EF
Cancer Detect Prev; 1985; 8(1-2):95-100. PubMed ID: 4064056
[TBL] [Abstract][Full Text] [Related]
11. Changes in management techniques and patterns of disease recurrence over time in patients with breast carcinoma treated with breast-conserving therapy at a single institution.
Pass H; Vicini FA; Kestin LL; Goldstein NS; Decker D; Pettinga J; Ingold J; Benitez P; Neumann K; Rebner M; Dekhne N; Martinez A
Cancer; 2004 Aug; 101(4):713-20. PubMed ID: 15305400
[TBL] [Abstract][Full Text] [Related]
12. [Therapy concept in differentiated thyroid gland carcinoma--results of 25 years with 257 patients].
Gemsenjäger E; Heitz PU; Martina B; Schweizer I
Praxis (Bern 1994); 2000 Nov; 89(44):1779-97. PubMed ID: 11109916
[TBL] [Abstract][Full Text] [Related]
13. Management of stage IV glottic carcinoma: therapeutic outcomes.
Spector GJ; Sessions DG; Lenox J; Newland D; Simpson J; Haughey BH
Laryngoscope; 2004 Aug; 114(8):1438-46. PubMed ID: 15280724
[TBL] [Abstract][Full Text] [Related]
14. [The effect of sera of breast cancer patients on NK cell activity].
Konjević G; Spuzić I
Srp Arh Celok Lek; 1995; 123(9-10):227-31. PubMed ID: 17974436
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of breast-conserving surgery for patients with breast carcinoma associated with nipple discharge.
Cabioglu N; Krishnamurthy S; Kuerer HM; Hunt KK; Singletary SE; Meric-Bernstam F; Ross MI; Feig BW; Ames FC; Babiera GV
Cancer; 2004 Aug; 101(3):508-17. PubMed ID: 15274063
[TBL] [Abstract][Full Text] [Related]
16. Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells.
Karcher J; Dyckhoff G; Beckhove P; Reisser C; Brysch M; Ziouta Y; Helmke BH; Weidauer H; Schirrmacher V; Herold-Mende C
Cancer Res; 2004 Nov; 64(21):8057-61. PubMed ID: 15520216
[TBL] [Abstract][Full Text] [Related]
17. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.
Peoples GE; Gurney JM; Hueman MT; Woll MM; Ryan GB; Storrer CE; Fisher C; Shriver CD; Ioannides CG; Ponniah S
J Clin Oncol; 2005 Oct; 23(30):7536-45. PubMed ID: 16157940
[TBL] [Abstract][Full Text] [Related]
18. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
[TBL] [Abstract][Full Text] [Related]
19. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Peoples GE; Holmes JP; Hueman MT; Mittendorf EA; Amin A; Khoo S; Dehqanzada ZA; Gurney JM; Woll MM; Ryan GB; Storrer CE; Craig D; Ioannides CG; Ponniah S
Clin Cancer Res; 2008 Feb; 14(3):797-803. PubMed ID: 18245541
[TBL] [Abstract][Full Text] [Related]
20. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
